{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:07:43Z","timestamp":1793394463864,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":373,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>We aimed to determine the use of sodium\u2013glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real-life setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED\u2013HEART study is a multicentre, cross-sectional and observational study that included HF patients in the outpatient setting regardless of ejection fraction from 19 cardiology centres between August 2023 and December 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study population consisted of 1923 patients with HF, predominantly men (61.2%), with a median age of 66 (range: 19\u2013101) years. Overall, 925 patients (48.1%) were receiving SGLT2is. Among the study population, 22.1% had HF with preserved ejection fraction, 21.5% had HF with mildly reduced ejection fraction, 56.4% had HF with reduced ejection fraction and the use of SGLT2is was 42.0%, 47.9% and 50.6% in each group, respectively (P = 0.012). The use of SGLT2is was 76.6% in patients with HF and diabetes, 19.8% in patients with HF and chronic kidney disease and 26.8% in patients without diabetes and chronic kidney disease (P &amp;lt; 0.001). Higher education level [odds ratio (OR): 1.80; 95% confidence interval (CI): 1.06\u20133.05; P = 0.027], higher household income (OR: 3.46; 95% CI: 1.27\u20139.42; P = 0.015), New York Heart Association functional class IV (OR: 2.72; 95% CI: 1.16\u20136.35; P = 0.021), diabetes (OR: 9.42; 95% CI: 6.72\u201313.20; P &amp;lt; 0.001), the use of angiotensin receptor\u2013neprilysin inhibitors (ARNis) (OR: 4.09; 95% CI: 2.39\u20137.01; P &amp;lt; 0.001), the use of mineralocorticoid receptor antagonists (MRAs) (OR: 2.02; 95% CI: 1.49\u20132.75; P &amp;lt; 0.001), the use of loop diuretics (OR: 1.62; 95% CI: 1.18\u20132.22; P = 0.003) and the use of thiazide diuretics (OR: 1.72; 95% CI: 1.30\u20132.29; P &amp;lt; 0.001) were independently associated with the use of SGLT2is. Conversely, atrial fibrillation (OR: 0.63; 95% CI: 0.45\u20130.88; P = 0.008), chronic kidney disease (OR: 0.53; 95% CI: 0.37\u20130.76; P = 0.001), the use of dihydropyridine calcium channel blockers (OR: 0.68; 95% CI: 0.48\u20130.98; P = 0.042) and the use of statins (OR: 0.67; 95% CI: 0.49\u20130.91; P = 0.010) were independently associated with the non-use of SGLT2is.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The RED\u2013HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF. These results suggest that there is a need for organized action and close collaboration between healthcare providers to improve the implementation of SGLT2is, especially in patients with HF with preserved ejection fraction and chronic kidney disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15049","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T04:23:25Z","timestamp":1727497405000},"page":"434-446","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Real-World Data on Empagliflozin and Dapagliflozin Use in Patients with HEART Failure: The RED\u2013HEART Study"],"prefix":"10.1093","volume":"12","author":[{"given":"Umut","family":"Kocabas","sequence":"first","affiliation":[{"name":"Department of Cardiology, Ba\u015fkent University \u0130zmir Hospital , \u0130zmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isil","family":"Ergin","sequence":"additional","affiliation":[{"name":"Department of Public Health, Faculty of Medicine, Ege University , \u0130zmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veysel","family":"Yavuz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Akhisar Mustafa Kirazoglu State Hospital , Manisa ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Alt\u0131n","sequence":"additional","affiliation":[{"name":"Department of Cardiology, \u0130zmir University of Economics, Faculty of Medicine, Medical Point Hospital , \u0130zmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Gaziantep University Medical School , Gaziantep ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcls\u00fcm Meral","family":"Y\u0131lmaz \u00d6ztekin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Health Sciences, Antalya Training and Research Hospital , Antalya ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Do\u011fdu\u015f","sequence":"additional","affiliation":[{"name":"Department of Cardiology, \u0130zmir University of Economics, Faculty of Medicine, Medical Point Hospital , \u0130zmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selda","family":"Murat","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Eski\u015fehir Osmangazi University , Eski\u015fehir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bekta\u015f","family":"Murat","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Eski\u015fehir City Hospital , Eski\u015fehir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tar\u0131k","family":"K\u0131vrak","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Firat University Medical School , El\u00e2z\u0131\u011f ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilay","family":"Karabulut","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital , Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersin","family":"Kaya","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dr Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital , \u0130zmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130brahim Halil","family":"\u00d6zdemir","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Manisa City Hospital , Manisa ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cennet","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital , Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma \u00d6zge","family":"Salk\u0131n","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Seyhan State Hospital , Adana ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"\u00d6z\u00e7al\u0131k","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ba\u015fkent University \u0130zmir Hospital , \u0130zmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeyda G\u00fcnay","family":"Polatkan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bursa Uludag University, Faculty of Medicine , Bursa ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahri","family":"\u00c7akan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cerkezkoy State Hospital , Tekirda\u011f ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taner","family":"\u015een","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kutahya Health Sciences University , K\u00fctahya ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Karabulut","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Istanbul Ac\u0131badem International Hospital , Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem","family":"\u00c7akal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Haseki Training and Research Hospital , Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersan","family":"Oflar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital , Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dcmit Ya\u015far","family":"Sinan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Istanbul University-Cerrahpasa Institute of Cardiology , Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Yener\u00e7a\u011f","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Samsun University, Faculty of Medicine , Samsun ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u011fur \u00d6nsel","family":"T\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of Cardiology, \u0130zmir University of Economics, Faculty of Medicine, Medical Point Hospital , \u0130zmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"key":"2026012113063011000_ehf215049-bib-0001","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113063011000_ehf215049-bib-0002","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1002\/ehf2.14559","article-title":"Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction","volume":"10","author":"Kocaba\u015f","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026012113063011000_ehf215049-bib-0003","doi-asserted-by":"publisher","first-page":"32","DOI":"10.14744\/AnatolJCardiol.2020.91771","article-title":"Adherence to guideline-directed medical and device Therapy in outpAtients with heart failure with reduced ejection fraction: The ATA study","volume":"24","author":"Kocaba\u015f","year":"2020","journal-title":"Anatol J Cardiol"},{"key":"2026012113063011000_ehf215049-bib-0004","doi-asserted-by":"publisher","first-page":"41","DOI":"10.14744\/AnatolJCardiol.2020.62747","article-title":"Heart failure guidelines implementation: Lifting barriers using registries and networks","volume":"24","author":"Keramida","year":"2020","journal-title":"Anatol J Cardiol"},{"key":"2026012113063011000_ehf215049-bib-0005","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113063011000_ehf215049-bib-0006","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113063011000_ehf215049-bib-0007","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012113063011000_ehf215049-bib-0008","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012113063011000_ehf215049-bib-0009","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American College of Cardiology Solution Set Oversight Committee","volume":"77","author":"Maddox","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012113063011000_ehf215049-bib-0010","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026012113063011000_ehf215049-bib-0011","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jchf.2019.12.015","article-title":"Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF: The CHAMP-HF registry","volume":"8","author":"Vaduganathan","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026012113063011000_ehf215049-bib-0012","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/ejhf.2131","article-title":"Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: Data from the Swedish Heart Failure Registry","volume":"23","author":"Becher","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113063011000_ehf215049-bib-0013","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/ejhf.2971","article-title":"Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry","volume":"25","author":"Stolfo","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113063011000_ehf215049-bib-0014","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ejhf.2397","article-title":"Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113063011000_ehf215049-bib-0015","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.cardfail.2022.04.011","article-title":"Eligibility for dapagliflozin and empagliflozin in a real-world heart failure population","volume":"28","author":"Thorvaldsen","year":"2022","journal-title":"J Card Fail"},{"key":"2026012113063011000_ehf215049-bib-0016","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/ejhf.2149","article-title":"Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction","volume":"23","author":"Packer","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113063011000_ehf215049-bib-0017","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/ejhf.2206","article-title":"Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"Rosano","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113063011000_ehf215049-bib-0018","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure\u2014Optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026012113063011000_ehf215049-bib-0019","doi-asserted-by":"publisher","first-page":"19","DOI":"10.30770\/2572-1852-94.2.19","article-title":"Clinical inertia and outpatient medical errors","volume":"94","author":"O\u2019Connor","year":"2008","journal-title":"J Med Regul"},{"key":"2026012113063011000_ehf215049-bib-0020","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.jchf.2023.06.022","article-title":"Clinical inertia among outpatients with heart failure: Application of treatment nonintensification taxonomy to EPIC-HF trial","volume":"11","author":"Swat","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026012113063011000_ehf215049-bib-0021","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamacardio.2020.0640","article-title":"Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT trial: A secondary analysis of a randomized clinical trial","volume":"5","author":"Fiuzat","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026012113063011000_ehf215049-bib-0022","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s10741-023-10325-2","article-title":"Guideline-directed medical therapy for HFrEF: Sequencing strategies and barriers for life-saving drug therapy","volume":"28","author":"Malgie","year":"2023","journal-title":"Heart Fail Rev"},{"key":"2026012113063011000_ehf215049-bib-0023","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113063011000_ehf215049-bib-0024","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2026012113063011000_ehf215049-bib-0025","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): A multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026012113063011000_ehf215049-bib-0026","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7326\/M22-2904","article-title":"Diabetes management in chronic kidney disease: Synopsis of the KDIGO 2022 clinical practice guideline update","volume":"176","author":"Navaneethan","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026012113063011000_ehf215049-bib-0027","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1177\/1403494820917534","article-title":"Does household income mediate the association between education and health in Canada?","volume":"49","author":"Veenstra","year":"2021","journal-title":"Scand J Public Health"},{"key":"2026012113063011000_ehf215049-bib-0028","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.healthpol.2021.04.006","article-title":"The prevalence and determinants of unmet health care needs in Turkey","volume":"125","author":"Ba\u015far","year":"2021","journal-title":"Health Policy"},{"key":"2026012113063011000_ehf215049-bib-0029","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012113063011000_ehf215049-bib-0030","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113063011000_ehf215049-bib-0031","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012113063011000_ehf215049-bib-0032","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ejhf.2743","article-title":"Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: An international cardiology survey","volume":"25","author":"Fauvel","year":"2023","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/1\/434\/64512836\/eschf_12_1_434.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/1\/434\/64512836\/eschf_12_1_434.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:06:40Z","timestamp":1769018800000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/1\/434\/8261834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,9,28]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15049","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"2024-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}